

## REMARKS

### Elections/Restrictions

Applicant elects with traverse to prosecute Group V, claims 6-13, drawn to diazines with two heterorings (where R<sup>1</sup> is diazine, or diazine fused to 5-membered heteroring), classified in class 544, subclass 236, 237, 353, and 354 with traverse.

In the specification, the paragraph beginning at page 1, line 2, has been amended to represent related U.S. priority applications.

Claims 1-5 and 14-20 have been canceled.

Date: July 17, 2003

Respectfully Submitted,

Joseph F. Reidy  
Joseph F. Reidy  
Attorney for Applicants  
Reg. No. 39,340

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-7320  
Fax: (858) 678-8233